Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 1-2/2024

Open Access 07.06.2023 | short report

The positive effect of spermidine in older adults suffering from dementia after 1 year

verfasst von: Thomas Pekar, Aribert Wendzel, Reinhart Jarisch

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2024

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Summary

Background

A positive effect of the effect of a 3-month oral spermidine intake on memory performance has already been demonstrated. The continuation of this study aimed to examine whether there could be observed an improvement in memory performance after one year.

Method

45 residents of the nursing home “Gepflegt Wohnen” in Hart bei Graz, Styria, Austria, were given a daily dose of 3.3 mg spermidine in their diet for one year.

Results

The comparison of the MMSE test results at baseline and after one year demonstrated a significant (p < 0.001) difference. The mean improvement is 5 points.

Conclusion

The new results confirm the already proven positive effect of oral spermidine intake on memory performance.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Based on our promising results, according to which the oral intake of spermidine has already shown a positive effect on memory performance after 3 months [1], the nursing home group participating in the study decided to change the meals of all residents to a spermidine-rich diet. To ensure a daily intake of at least 3.3 mg spermidine per day, attention was paid to enriching as many meals as possible with spermidine. After 1 year, the residents of one house (Hart bei Graz) were again subjected to CERAD-Plus testing. We now present the results of this test.

Material and methods

In total, 45 older individuals (MD 83, SD 9.5 years of age) participated in the follow up study. Participants were recruited via the director of nursing in the rest home in Hart bei Graz of the “Gepflegt Wohnen” group in Styria, Austria. People aged between 60 and 100 years were eligible for participation in the study. Furthermore, they had to not only take part in the CERAD-Plus test at the beginning and after 1 year but also continue their previous medication. Exclusion criteria comprised receiving antidementia medication, changing their previous medication, withdrawal by choice or participation in another study. Written informed consent was obtained from all participants in accordance with the Ethics Committee of the Medical University of Graz (30-280 ex 17/18). For those who were not able to understand the study, relatives or administrators provided consent.
Statistical analyses were carried out with the SPSS 26 statistical package (PASW, SPSS; IBM, Armonk, NY, USA). The Wilcoxon test for paired samples was applied for two-point comparison. The level of significance was set at a p-value of less than 0.05.

Results

The comparison of the results of the mini mental state examination (MMSE) showed a significant difference (p < 0.001). The median improvement was 5 points (Fig. 1).
Looking at the details, after 1 year an improvement in cognitive performance in 42% of the participants, a deterioration in 28% could be observed and 30% of the participants showed no change in MMSE.
A statistically significant improvement was also found in other categories of the CERAD-Plus test. In the “learn, recall and recognize a word list” section there was a medium improvement of 2 points (p = 0.047) and the evaluation of the item “sign and recall figures” also revealed an increase of 2 points (p = 0.039).

Discussion

In a recently published study, in contrast to our results, no effect could be demonstrated after 1 year of spermidine intake [2]. We see one reason for this in the too low spermidine concentration of 0.9 mg, which is below the concentration we used in our control group in our most recently published work [1].
In a previous work we could show that there is a positive correlation between serum spermidine content and the MMSE score [3]. This fact was questioned in a letter to the editor due to too low R2 levels in the correlation analysis carried out [4]. A recently published study with a sample size of 3774 also described a correlation between serum spermidine levels and cognitive impairments [5]. In addition, the authors concluded that monitoring the spermidine levels may be helpful for reducing the incidence of cognitive impairments. We agree with this because, based on our findings, we believe that it is important to counteract low serum spermidine levels early on to reduce the risk of dementia.
In summary, the results after 1 year show a continuation of the positive effect of oral spermidine intake for patients with neurocognitive impairment.

Limitations

As all subjects received the same dose of spermidine, blinding was not possible. The small number of participants should also be mentioned; however, as a small sample size usually results in a type II error and the null hypothesis was not accepted, this does not constitute a problem. Nevertheless, the results should be verified in a follow-up study with a larger sample.

Conflict of interest

T. Pekar, A. Wendzel and R. Jarisch declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
2.
Zurück zum Zitat Schwarz C, Benson GS, Horn N, Wurdack K, Grittner U, Schilling R, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: a randomized clinical trial. JAMA Netw Open. 2022;5(5):E2213875. CrossRefPubMedPubMedCentral Schwarz C, Benson GS, Horn N, Wurdack K, Grittner U, Schilling R, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: a randomized clinical trial. JAMA Netw Open. 2022;5(5):E2213875. CrossRefPubMedPubMedCentral
Metadaten
Titel
The positive effect of spermidine in older adults suffering from dementia after 1 year
verfasst von
Thomas Pekar
Aribert Wendzel
Reinhart Jarisch
Publikationsdatum
07.06.2023
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2024
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-023-02226-z

Weitere Artikel der Ausgabe 1-2/2024

Wiener klinische Wochenschrift 1-2/2024 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month

mitteilungen der gesellschaft der ärzte in wien

Krebsgesellschaft & Wiener Rettung einst und jetzt